DUBAI, UAE/PRNewswire/A unique non-estrogen prescription therapy, Intrarosa(TM), has been approved by the US Food and Drug Administration (FDA) and by the European Medical Agency (EMA), for the treatment of the most bothersome symptom of vulvovaginal atrophy, due to menopause, known as dyspareunia.
Mundipharma has been granted the commercial rights to Intrarosa(TM) (Prasterone) in the Middle East and Africa as part of an agreement signed between Mundipharma and Endoceutics, Inc.
Photo: https://mma.prnewswire.com/media/685081/Mundipharma_Logo.jpg
https://mma.prnewswire.com/media/685082/Endoceutics_Logo.jpg
Source: Mundipharma
Contacts:
Mundipharma META,Patrycja Czoch,
Corporate Communications Manager,
Mob: +97-1-50-85 12700,
Patrycja.Czoch@mundipharma.ae
